Laparoscopic Instruments Market worth $15.86 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global laparoscopic instruments market will grow from $10.74 billion in 2026 to $15.86 billion by 2031, an 8.1% CAGR, driven by minimally invasive-surgery adoption, chronic-disease prevalence, and advances in imaging, energy devices, and robotic assistance. Laparoscopes and general-surgery applications are expected to hold the largest market shares, while North America remained the leading region in 2025. Industry activity includes Advanced Medical Solutions' €132.5 million July 2024 acquisition of Peters Surgical, plus a potential €8.9 million earnout, and Microline Surgical's November 2023 acquisition of REVEEL laparoscopic liver-retraction assets.

Analysis

This is directionally supportive for procedure-exposed consumables, but the forecast itself is not a near-term earnings catalyst: market-research TAM estimates rarely alter hospital capital budgets or procedure schedules. CNMD has the cleanest operational sensitivity because recurring single-use general-surgery products convert incremental case volume into revenue with limited incremental selling expense; sustained mix toward AirSeal/biliary-type consumables can expand gross margin faster than reported procedure growth. JNJ, MDT and SYK have sufficiently diversified portfolios that conventional laparoscopy is unlikely to move consolidated estimates.

The more consequential competitive variable is the boundary between conventional laparoscopy and robotic-assisted surgery. If robotic penetration accelerates, suppliers of reusable scopes and conventional instruments may face lower unit growth or pricing pressure even while minimally invasive procedure volumes rise; JNJ is better positioned to internalize that substitution through its robotics ecosystem, while CNMD's upside depends on maintaining disposable attach rates regardless of surgical platform. Hospital sterilization labor, infection-control protocols, and ambulatory-surgery-center migration also favor disposable or reposable models over fully reusable instruments, creating a multi-year mix tailwind but potentially raising procurement-driven price scrutiny.

Consensus is likely to overread the broad market growth rate as an equal benefit across incumbents. The investable question is whether companies can outgrow procedure volumes through consumable content per case, share gains, and price realization. Over the next 1-3 months, quarterly commentary on general-surgery organic growth, AirSeal utilization, and elective-case trends matters more than this publication; over 6-18 months, robotic substitution and hospital capital-budget discipline determine whether the category supports multiple expansion.

Key Decisions for Investors

• Maintain a 6-12 month relative long CNMD / short MDT pair, sized modestly: CNMD offers greater incremental exposure to recurring general-surgery consumables, while MDT's broader medtech earnings dilute this theme. Reassess if CNMD General Surgery organic growth falls below mid-single digits for two quarters or gross margin contracts despite volume growth.
• Do not add directional JNJ or SYK exposure on this item alone. Their laparoscopic exposure is too small versus pharmaceuticals (JNJ) and orthopedics/neurotechnology (SYK); require evidence of surgical segment guidance increases or measurable robotics cross-selling before treating this as an earnings catalyst.
• Set an earnings watch on CNMD: a high-single-digit general-surgery growth print accompanied by stable-to-higher gross margin would validate a consumable-led share thesis and justify adding on post-results weakness; weak AirSeal utilization or adverse hospital purchasing commentary falsifies it.
• Monitor Intuitive Surgical (ISRG) procedure growth and JNJ robotic-install disclosures as a 6-18 month hedge signal. Faster robotic adoption without evidence that CNMD consumables travel across platforms argues for reducing CNMD exposure rather than extrapolating conventional-laparoscopy TAM growth.